Cargando…
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have largely been focused on blocking angiogenesis. Sunitin...
Autores principales: | Azijli, Kaamar, Gotink, Kristy J., Verheul, Henk M.W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Codon Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345522/ https://www.ncbi.nlm.nih.gov/pubmed/28326274 http://dx.doi.org/10.15586/jkcvhl.2015.44 |
Ejemplares similares
-
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015) -
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016) -
Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014) -
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009) -
Drug resistance-related sunitinib sequestration in autophagolysosomes of endothelial cells
por: Wu, Shuang, et al.
Publicado: (2019)